C. Yong Kang


Postdoc:  University of Wisconsin-Madison, USA

PhD:  McMaster University, Canada



Office:  Siebens-Drake Research Institute, Room 129

Phone:  519.661.3226

Email:  cykang@uwo.ca  

Lab Website: Kang Lab Website

Area of Study:

Development of vaccines against human viral diseases

Fields of Interest:

-Development of anti-viral vaccines.
-Investigation of the mechanism of viral interference mediated by DI particles

Research Profile

The Kang Lab has developed HIV vaccine using a genetically modified and killed whole-HIV-1 (SAV001) and completed the Phase I human clinical trial successfully. His team is now preparing for the Phase II human clinical trial. He has also developed a dual-serotype VSV vector system for recombinant vaccine development using genetically modified avirulent M gene mutants of both Indiana serotype and New Jersey serotype of VSV. With this platform technology Kang Lab has developed vaccines against HIV, MERS-CoV, Ebolavirus, and Zikavirus. He has published 142 peer reviewed papers and 161 conference proceedings & abstracts. He has 14 international patents covering over 75 countries.


Publication Profile

Selected Publications:

DOI:10.15406/jhvrv.2016.04.00125, 2016
DOI:10.1186/s12977-016-0317-2, http://rdcu.be/m4U0, 2016
DOI:10.1186/s12981-017-0176-5, 2017
https://insight.jci.org/articles/view/126047 2019